Home

Insights

Natco Pharma Ltd dividend

Natco Pharma Ltd dividend

download
stocks purchased

₹ 10.8 Cr

Volume transacted

stocks purchased

90.4 K

stocks traded

Image

Natco Pharma Ltd

NSE: NATCOPHARM

DPS

5.5

Last updated : FY 2023

Key Highlights

    The Dividend per Share of Natco Pharma Ltd is ₹ 5.5 as of 2023 .a1#The Dividend Payout of Natco Pharma Ltd changed from 17.1 % on March 2019 to 15.75 % on March 2023 . This represents a CAGR of -1.63% over 5 years. a1#The Latest Trading Price of Natco Pharma Ltd is ₹ 1166 as of 28 Jun 15:30 .a1#The Market Cap of Natco Pharma Ltd changed from ₹ 10515 crore on March 2019 to ₹ 10289 crore on March 2023 . This represents a CAGR of -0.43% over 5 years. a1#The Revenue of Natco Pharma Ltd changed from ₹ 918.9 crore to ₹ 1110 crore over 8 quarters. This represents a CAGR of 9.92% a1#The EBITDA of Natco Pharma Ltd changed from ₹ 429.6 crore to ₹ 539.3 crore over 8 quarters. This represents a CAGR of 12.04% a1#The Net Pr of Natco Pharma Ltd changed from ₹ 320.4 crore to ₹ 386.3 crore over 8 quarters. This represents a CAGR of 9.80% a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

Share Price Vs Dividend Yield

swot
swot

Fundamental Metrics

Market Cap

20,889 Cr

EPS

77.5

P/E Ratio (TTM) *

15.1

P/B Ratio (TTM) *

3.6

DTE *

0.1

ROE *

23.7

ROCE *

27.2

Dividend Yield *

0.98

DPS *

5.5

Dividend Payout *

15.75

Ann.Dividend % *

275

* All values are consolidated

Last Updated time: 01 Jul 15:19 PM

* All values are consolidated

Last Updated time: 01 Jul 15:19 PM

×

Historical Dividend Payout of Natco Pharma Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Natco Pharma Ltd

Period
Mar '1917
Mar '2026
Mar '2131
Mar '2259
Mar '2316

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

Natco Pharma Ltd

NSE: NATCOPHARM

PRICE

1166.3

14.40 (1.25%)

stock direction

Last updated : 28 Jun 15:30

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Historical Market Cap of Natco Pharma Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Natco Pharma Ltd

Period
Mar '1910515
Mar '209215
Mar '2115046
Mar '2213822
Mar '2310290

* All values are a in crore

×

Historical Revenue of Natco Pharma Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Natco Pharma Ltd

Period
Jun '22919
Sep '22453
Dec '22513
Mar '23927
Jun '231160
Sep '231061
Dec '23796
Mar '241110

* All values are a in crore

×

Historical EBITDA of Natco Pharma Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Natco Pharma Ltd

Period
Jun '22430
Sep '22116
Dec '22127
Mar '23368
Jun '23548
Sep '23487
Dec '23305
Mar '24539

* All values are a in crore

×

Historical Net Profit of Natco Pharma Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Natco Pharma Ltd

Period
Jun '22320
Sep '2257
Dec '2262
Mar '23276
Jun '23420
Sep '23369
Dec '23213
Mar '24386

* All values are a in crore

About Natco Pharma Ltd

About Natco Pharma Ltd

    Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). The Company's focus is primarily on niche therapeutic areas and complex products. It sells products in over 40 countries. FDF products are sold in the United States, India, Europe and the rest of the world (RoW). Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. Natco Pharma was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited. It became a deemed public company with effect from 1 July 1992. The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993. The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. In 1988, the company inaugurated a Parenterals manufacturing facility at Nagarajuna Sagar, Telangana. In 1993, the company inaugurated its chemical division at Mekaguda, Telangana. On 1 April 1995, Natco Parenterals Limited, Natco Laboratories Limited and Dr. Karanth Pharma Labs Private Limited merged with Natco Pharma. In 1997, Natco Pharma inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad. In 2003, Natco Pharma launched its Oncology division with introduction of flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia. In 2006, Natco Pharma inaugurated a world class finished dosage facility at Dehradun, Uttarakhand. In 2007, Natco Pharma launched its first abbreviated new drug application (ANDA) in the US market. During the year, the company acquired Savemart Pharmacy in USA. In 2008, Natco Pharma filed its first Paragraph IV filing in the US market. In 2009, Natco Pharma's turnover reached $100 million milestone. In 2011, Natco Pharma and Levomed LLC, USA formed a joint venture company, Natcofarma Do Brasil for sales and distribution in Brazil. In 2012, Natco Pharma won the first ever compulsory license from Bayer for its patent-protected anti-cancer drug Nexavar in India. During the year, the company established Natco Pharma Asia Pte Ltd as a wholly owned subsidiary for sales and distribution in Singapore. In 2013, Natco Pharma established a subsidiary Natco Pharma Canada for sales and distribution in Canada. In 2014, Natco Pharma established a subsidiary Natco Pharma Australia Pty Ltd for sales and distribution in Australia. On 9 March 2015, Natco Pharma announced that it has launched the first generic version of sofosbuvir in Nepal. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. On 11 March 2015, Natco Pharma announced that it is the first company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India). Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India. The Board of Directors of Natco Pharma at its meeting held on 30 March 2016 approved the sale of its Save Mart Pharmacy Store located in the USA to CARE MART Inc. The Save Mart Pharmacy Store is owned by Natco Pharma Inc., a wholly owned subsidiary of the company, and is considered as a non-core part of the business. On 12 December 2016, Natco Pharma announced the launch of the first generic version of Oseltamivir oral capsules, 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the USA market. In 2017, Natco Pharma launched new cardiology and diabetology division for Indian market. On 2 January 2017, Natco Pharma announced that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa. Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin. On 17 May 2017, Natco Pharma announced that its partner Dr. Reddy's Laboratories Ltd. has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market. On 5 October 2017, Natco Pharma announced that its marketing partner Mylan N.V., has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone 40 mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP-rated, substitutable generic version of Teva's Copaxone 20 mg/mL. These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced. On 4 November 2017, Natco Pharma announced that it has executed definitive agreement and subscribed to 7.50% of the paid-up equity share capital of OMRV Hospitals Private Limited (OMRV). The investment amount was Rs 7.50 crore. OMRV operates under brand name of PACE Hospital which is a super specialty hospital presently operating in Hyderabad, Telangana focused on tertiary care services in the field of Medical and Surgical Gastroenterology, Hepatology, Nephrology, Urology, GI Oncology and Andrology. The Committee of Directors of Natco Pharma at its meeting held on 14 December 2017 approved allocation of 1 crore Equity Shares at the issue price of Rs 915 per Equity (including a premium of Rs. 913 per Equity Share) upon the closure of the issue, to eligible qualified institutional buyers pursuant to the QIP amounting to an Issue size of Rs 915 crore. On 17 February 2018, Natco Pharma completed regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12th February, 2018 to 16th February, 2018, where the regulatory audit resulted in zero observations (no form 483 issued). During FY 2019-20, NATCO had 8 launches in the domestic market, 5 in cardiology and diabetology segment, and 3 in oncology segment. It launched a combination drug Vildanat M (Vildagliptin and Metformin) for diabetes, to achieve better blood glucose control and improve therapy compliance. During the period 2019-20, NATCO Life sciences Philippines Inc. was formed a fully owned subsidiary in the Philippines. During the year, it launched an FDC of Sofosbuvir-Daclatasvir tablets to treat Hepatitis C under the brand name 'Hepcinat Plus' and an oral fixed-dose combination of Sofosbuvir and Velapatasvir under their brand 'Velpanat'. The Company has 7 subsidiaries as on March 31, 2020. The Company has 7 international subsidiaries including 1 step-down subsidiary as on 31st March, 2021. In FY 2020-21, the Company launched generic Lenalidomide in South Africa. The Company has 8 international subsidiaries including 2 step-down subsidiaries as on 31st March, 2022. During FY 2021-22, Company through NATCO Pharma Inc., USA a wholly owned Subsidiary of Company acquired Dash Pharmaceuticals LLC, USA effective on 1st January, 2022, where Dash Pharmaceuticals LLC, USA is a step-down wholly owned Subsidiary Company of the Company. In Philippines, it launched first product, Liposomal Doxorubicin. In Australia, it received approval for Lenalidomide and Pomalidomide. It launched Sorafenib tablet in Taiwan with one year exclusivity. It launched first generic of Abiraterone tablets in Taiwan & Indonesia. It launched the Bendamustine Injection and Anastrozole tablets by the subsidiary named, Natco Lifesciences Philippines Inc. It launched the first generic of Oseltamivir in Brazil. It launched Everolimus in the US market. It launched 4 new products launched in 2021-22 such as Xpreza tablets, Pazonat, Cazanat and Tipanat for pateints suffering from liver, kidney and colorectal cancer. 11 new products launched in 2022-23. The Company launched Chlorantraniliprole (CTPR) pesticide formulation and its combination products in liquid and granule forms. It launched a first generic alternative to the cancer drug Pomalidomide capsules sold under the Pomalyst brand; launched Apixaban, Azacitidine in Philippines, Gefitinib, launched Oseltamivir capsules in the China market in 2023. It launched two Chlorantraniliprole (CTPR) pesticide formulation under brand names NATGEN and NATERRA and CTPR combination products under the brand names NATVOL and NATLIGO. It launched the first generic of Nat-Pomalidomide, Nat-Apixaban, and Nat-Teriflunomide in the market in the year 2023.

Natco Pharma Ltd News Hub

News

Natco Pharma Ltd spurts 5.12%, rises for fifth straight session

Natco Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 115...

Read more

11 Jun 202413:00

News

Natco Pharma Ltd spurts 4.93%, up for third straight session

Natco Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1084....

Read more

07 Jun 202413:05

News

Natco Pharma hits 52-week high as PAT rises 40% YoY in Q4

Profit before tax for March 2024 quarter stood at Rs 477.6 crore, up 47.23% from Rs 324.4 ...

Read more

28 May 202410:58

News

Natco Pharma Ltd rises for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 990...

Read more

14 May 202413:05

News

Natco Pharma to hold board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 27 May 2024 P...

Read more

09 May 202416:50

News

Natco Pharma update on legal complaint filed in US

NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (t...

Read more

18 Apr 202409:30

FAQs for dividends of Natco Pharma Ltd

What is the current market price of Natco Pharma Ltd Ltd as of July 1, 2024?

The current market price of Natco Pharma Ltd Ltd stands at 1166.3 per share.

What dividend did Natco Pharma Ltd declare in the last fiscal year?

In the last fiscal year, Natco Pharma Ltd declared a dividend totaling ₹9.5.

What is the most recent dividend declared by Natco Pharma Ltd?

Natco Pharma Ltd recently declared a dividend of 1.3 in the latest quarter

How many times has Natco Pharma Ltd declared dividends in the current fiscal year

Natco Pharma Ltd has declared dividends 4 times totaling ₹10 in the current fiscal year (FY2023-2024).

How many times did Natco Pharma Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Natco Pharma Ltd declared dividends 4 times totaling ₹6.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199